{
  "id": 5312663,
  "title": "Summit, Akeso say ivonescimab clears OS bar in Phase 3 lung cancer trial",
  "url": "https://urgent.news/2026/09/03/summit-akeso-say-ivonescimab-clears-os-bar-in-phase-3-lung-cancer",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-03T11:12:36.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/summit-akeso-say-ivonescimab-clears-os-bar-in-phase-3-lung-cancer-trial/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Akeso has announced that its Phase 3 trial for ivonescimab, a PD-1xVEGF bispecific, met the key secondary endpoint of overall survival (OS) in certain lung cancer patients. According to Vietnam Investment Review, the trial, called HARMONi-2, compared ivonescimab to pembrolizumab as a first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1.\n\nThe results showed that ivonescimab demonstrated a statistically significant and clinically meaningful improvement in OS over pembrolizumab. This is a notable achievement, as the HARMONi-2 study is the first randomized, double-blind Phase III trial to show a significant positive outcome against pembrolizumab in this setting.\n\nIn a previous analysis in May 2024, ivonescimab had already met its primary endpoint of progression-free survival (PFS), with a median PFS of 11.14 months compared to 5.82 months for pembrolizumab, as per Vietnam Investment Review. Detailed data from the interim OS analysis will be presented at an upcoming international medical conference and published in a peer-reviewed journal.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}